Amylase variants
CA 2821537 C · Owner: Novozymes A/S · Inventors: Bisgard-Frantzen, Henrik; Svendsen, Allan; Borchert, Torben Vedel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A variant of a parent .alpha.-amylase, which parent .alpha.-amylase (i) has an amino acid sequence selected from the amino acid sequences shown in SEQ ID NO:1 SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:7 respectively; or (ii) displays at least 80% homology with one or more of these amino acid sequences; and/or displays immunological cross-reactivity with an antibody raised against a .alpha.-amylase having one of these amino acid sequences; and/or is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding a .alpha.-amylase having one of these amino acid sequences; in which variant: (a) at least one amino acid residue of the parent .alpha.-amylase has been …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 5, 1996 and granted January 26, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 5, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 5, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.